title: Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia.
abstract: OBJECTIVE
  Few studies have prospectively examined remission and recovery as well as their predictors in schizophrenia simultaneously. Aims of the study were to identify remission and recovery rates as well as their predictors in schizophrenia.
  
  
  METHODS
  392 never-treated patients with schizophrenia were assessed over 3 years. Combined remission and recovery required concurrent achievement of symptomatic and functional remission as well as adequate quality of life for at least 6 and 24 months respectively. Predictors were analysed using stepwise logistic regression models.
  
  
  RESULTS
  At 3 years, remission rates for symptoms, functioning and subjective wellbeing were 60.3%, 45.4% and 57.0%; recovery rates were 51.7%, 35.0% and 44.3%. Of those, 28.1% were in combined remission and 17.1% in combined recovery. Predictors mainly included the baseline functional status and early remission within the first 3 months.
  
  
  CONCLUSIONS
  The proportion of patients who met combined remission or recovery criteria is low. Early treatment adaptations in case of early non-remission are mandatory.
authors.affiliation: Psychosis Early Detection and Intervention Centre, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. lambert@uke.uni-hamburg.de
authors.forename: M
authors.initials: M
authors.lastname: Lambert
authors.forename: D
authors.initials: D
authors.lastname: Naber
authors.forename: A
authors.initials: A
authors.lastname: Schacht
authors.forename: T
authors.initials: T
authors.lastname: Wagner
authors.forename: H-P
authors.initials: HP
authors.lastname: Hundemer
authors.forename: A
authors.initials: A
authors.lastname: Karow
authors.forename: C G
authors.initials: CG
authors.lastname: Huber
authors.forename: D
authors.initials: D
authors.lastname: Suarez
authors.forename: J M
authors.initials: JM
authors.lastname: Haro
authors.forename: D
authors.initials: D
authors.lastname: Novick
authors.forename: R W
authors.initials: RW
authors.lastname: Dittmann
authors.forename: B G
authors.initials: BG
authors.lastname: Schimmelmann
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D004651:Employment / Q000523:psychology; D005260:Female; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011788:Quality of Life; D012075:Remission, Spontaneous; D012559:Schizophrenia / Q000188:drug therapy / Q000453:epidemiology*; D012565:Schizophrenic Psychology; D012919:Social Behavior; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine